|1.||Bialer, Meir: 7 articles (09/2015 - 02/2004)|
|2.||Yagen, Boris: 5 articles (08/2015 - 06/2010)|
|3.||Finnell, Richard H: 4 articles (09/2015 - 06/2010)|
|4.||Shekh-Ahmad, Tawfeeq: 3 articles (08/2015 - 09/2013)|
|5.||McDonough, John H: 3 articles (08/2015 - 09/2013)|
|6.||Hen, Naama: 3 articles (02/2014 - 11/2011)|
|7.||Wlodarczyk, Bogdan J: 2 articles (09/2015 - 02/2014)|
|8.||Bialer, M: 2 articles (02/2013 - 11/2000)|
|9.||Wlodarczyk, Bogdan: 2 articles (11/2011 - 06/2010)|
|10.||Ogle, Krystal: 1 article (09/2015)|
|1.||Bipolar Disorder (Mania)
06/01/2010 - "We performed a double-blind, five-week, add-on, controlled trial of valnoctamide in mania. "
06/01/2010 - "Differences between valnoctamide and placebo were significant from week 3 to week 5. Valnoctamide could be an important valproate substitute for women of childbearing age with bipolar disorder who may become pregnant."
06/01/2010 - "Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial."
09/01/2015 - "Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system. "
02/01/2014 - "Valnoctamide (VCD), a central nervous system (CNS)-active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid (VPA), is currently undergoing phase IIb clinical trials in acute mania. "
04/01/1997 - "In the patients with epilepsy, valnoctamide kinetics was also reassessed after 8-day oral dosing at a dosage of 600 mg daily. "
04/01/1997 - "Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy."
09/01/2015 - "Based on the recent findings from animal studies, it has been proposed that the therapeutic use of valnoctamide, an anxiolytic drug developed in the early 1960s, be extended to treat other neurological disorders such as epilepsy and bipolar disease. "
04/01/1997 - "The observed pharmacokinetic differences between healthy subjects and patients with epilepsy are likely to be related to induction of metabolism of valnoctamide stereoisomers by carbamazepine."
04/01/1997 - "Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. "
06/01/2010 - "The purpose of this study was to evaluate the stereoselective pain relieving (antiallodynic) activity, antiallodynic-anticonvulsant correlation, teratogenicity and pharmacokinetic profile of two stereoisomers of valnoctamide (VCD), a CNS-active amide derivative of a chiral isomer of valproic acid (VPA). "
|4.||Nervous System Diseases (Neurological Disorders)
|5.||Partial Epilepsies (Epilepsy, Partial)
11/01/2000 - "In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy."
11/01/2000 - "We evaluated the effectiveness of the commonly used antiepileptic drug sodium valproate (400 mg/kg) and two of its amide derivatives, valpromide and valnoctamide (both 100 mg/kg), in an in vivo rat model of focal epilepsy. "
|1.||Valproic Acid (Valproate, Semisodium)
|4.||Risperidone (Risperdal Consta)